Indian drugmaker Syncom Formulations' Q2 revenue rises 16.8%
Overview
Indian drugmaker's Q2 consolidated revenue from operations rose 16.8% to INR 1.42 bln
Consolidated profit for the period rose 60.6% to INR 266.5 mln
Diluted EPS rose to INR 0.28 from INR 0.18
Outlook
Company did not provide specific financial guidance for upcoming quarters or full year in its press release
Result Drivers
PHARMA REVENUE – Pharmaceuticals drugs and formulations segment revenue rose about 16.5% to INR 1.47 bln from INR 1.26 bln yr/yr in Q2
OPERATING EXPENSES – Consolidated operating expenses rose nearly 7% to INR 1.12 bln
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Consol Revenue from OPS | INR 1.42 bln | ||
Q2 Consol Net Profit | INR 266.5 mln |
Reuters Recommended Reads
Nov 12 - India's P&G Hygiene and Health profit drops as costs bite
Nov 13 - Gillette India's quarterly profit rises as cost savings cushion commodity pressures
Nov 12 - Germany's Dermapharm 9M revenue rises on growth in branded pharmaceuticals segment
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)